These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1793213)

  • 1. Immunotoxins and cytokine toxin fusion proteins.
    Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
    Ann N Y Acad Sci; 1991 Dec; 636():233-50. PubMed ID: 1793213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotoxins and cytokine toxin fusion proteins.
    Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
    Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diphtheria-related peptide hormone gene fusions: a molecular genetic approach to chimeric toxin development.
    Murphy JR
    Cancer Treat Res; 1988; 37():123-40. PubMed ID: 2908622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotoxins for targeted cancer therapy.
    Kreitman RJ
    AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin.
    Peraino JS; Schenk M; Zhang H; Li G; Hermanrud CE; Neville DM; Sachs DH; Huang CA; Duran-Struuck R; Wang Z
    J Immunol Methods; 2013 May; 391(1-2):103-11. PubMed ID: 23470981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patents on immunotoxins and chimeric toxins for the treatment of cancer.
    Bachran C; Sutherland M; Bachran D; Fuchs H
    Recent Pat Drug Deliv Formul; 2007; 1(2):105-15. PubMed ID: 19075878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.
    Cheung LS; Fu J; Kumar P; Kumar A; Urbanowski ME; Ihms EA; Parveen S; Bullen CK; Patrick GJ; Harrison R; Murphy JR; Pardoll DM; Bishai WR
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):3100-3105. PubMed ID: 30718426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant toxins for the treatment of cancer.
    Kreitman RJ
    Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo.
    Kelley VE; Bacha P; Pankewycz O; Nichols JC; Murphy JR; Strom TB
    Proc Natl Acad Sci U S A; 1988 Jun; 85(11):3980-4. PubMed ID: 3131768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of targeted toxins.
    Frankel AE; Tagge EP; Willingham MC
    Semin Cancer Biol; 1995 Oct; 6(5):307-17. PubMed ID: 8562908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
    Shapiro ME; Kirkman RL; Kelley VR; Bacha P; Nichols JC; Strom TB
    Targeted Diagn Ther; 1992; 7():383-93. PubMed ID: 1633300
    [No Abstract]   [Full Text] [Related]  

  • 13. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
    Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
    Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant immunotoxins for the treatment of haematological malignancies.
    Kreitman RJ
    Expert Opin Biol Ther; 2004 Jul; 4(7):1115-28. PubMed ID: 15268678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.
    Lorberboum-Galski H
    Expert Opin Drug Deliv; 2011 May; 8(5):605-21. PubMed ID: 21453191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant fusion toxins--a new class of targeted biologic therapeutics.
    Woodworth TG; Nichols JC
    Cancer Treat Res; 1993; 68():145-60. PubMed ID: 8105849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphtheria toxin-based targeted toxin therapy for brain tumors.
    Li YM; Vallera DA; Hall WA
    J Neurooncol; 2013 Sep; 114(2):155-64. PubMed ID: 23695514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.
    Potala S; Sahoo SK; Verma RS
    Drug Discov Today; 2008 Sep; 13(17-18):807-15. PubMed ID: 18678276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting diphtheria toxin to growth factor receptors.
    Murphy JR; vanderSpek JC
    Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.